The North America Dry Eye Syndrome Treatment Market would witness market growth of 3.2% CAGR during the forecast period (2022-2028).
A robust and prospective pipeline has been created as a result of increased R&D efforts for the condition's treatment. This includes items like CyclASol, SURF-100, SURF-200, Pro-ocular, and OCS-02, which are projected to increase the patient population's inventory of available therapy alternatives. Additionally, NOV03 met every clinical target, and its introduction is expected to be soon. Geriatric population growth is anticipated to be a major market driver since older people's eyes produce fewer tears, which causes more evaporation and dryness.
A significant factor driving the growth of the dry eye syndrome treatment market is the rising occurrence of dry eye syndrome and the rising need for dry eye treatment to relieve various symptoms. During the forecast period, there will be opportunities for growth in the markets for eye care products and treatments for dry eye syndrome. This is due to the rapid increase in cases of the condition and the rising adoption of various treatments, such as artificial tears and dry eye treatment drops, for treating multiple symptoms. Additionally, the growing acceptance of femtosecond and excimer ophthalmic lasers for the treatment of dry eye conditions bodes well for the market's future.
In Canada, a prospective, multicenter, observational cross-sectional study was carried out at six locations across the country. This study offered crucial insights into the detrimental effects of DED in the context of Canada. In comparison to people with a moderate or mild condition, those with severe DED had higher indirect and direct costs as well as lower quality of life. Patients with DED and Sjögren's syndrome had worse quality of life (QoL) and higher expenses than those with DED alone. These studies present the possibility of rising cases of DED and its detrimental effects. These will propel the demands for treatment throughout the region, therefore, expediting the expansion of the dry eye syndrome treatment market.
The US market dominated the North America Dry Eye Syndrome Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,558.4 million by 2028. The Canada market is experiencing a CAGR of 5.6% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 4.6% during (2022 - 2028).
Based on Type, the market is segmented into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on Drug, the market is segmented into Restasis, Xiidra, Cequa, Eysuvis and Tyrvaya & Others. Based on Dosage, the market is segmented into Eye drops, Gels, Capsules & Tablets, Eye Solutions and Ointments. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Sales Channel, the market is segmented into OTC and Prescription. Based on Product, the market is segmented into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Dry Eye Syndrome Treatment Market is Estimated to reach $6.5 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson (Johnson & Johnson Services, Inc.), AbbVie, Inc., Bausch + Lomb Corporation (Bausch Health Companies, Inc.), Novartis AG, Sun Pharmaceuticals Industries Ltd., AFT Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., OASIS Medical, Inc., and Otsuka Pharmaceutical Co., Ltd.
By Type
By Drug
By Dosage
By Distribution Channel
By Sales Channel
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 